Showing 2571-2580 of 3039 results for "".
- ProQR Therapeutics and Yarrow Biotechnology Announce Exclusive License and Discovery Collaboration for Undisclosed Ophthalmic Targethttps://modernod.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/RTW Investments and ProQR Therapeutics announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is f
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- Mallinckrodt Presents Data Evaluating Acthar Gel for the Treatment of Severe Keratitis at ARVOhttps://modernod.com/news/mallinckrodt-presents-data-evaluating-acthar-gel-for-the-treatment-of-severe-keratitis-at-arvo/2479153/Mallinckrodt announced data from its phase 4, multicenter, open-label study to assess the efficacy and safety of Acthar Gel (repository corticotropin injection) in adult patients with treatment-resistant, severe noninfectious keratitis, a disease which involves painful
- Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meetinghttps://modernod.com/news/oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting/2479144/Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. The details of the presentation are as follows: Title: The Mouse Sodium Iodate Mo
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Allergan to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021https://modernod.com/news/allergan-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-2021/2479116/Allergan announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May
- Glaukos Announces Global Licensing Agreement Amendment with Intratus to Include the Treatment of Presbyopiahttps://modernod.com/news/glaukos-announces-global-licensing-agreement-amendment-with-intratus-to-include-the-treatment-of-presbyopia/2479115/Glaukos announced that it has entered into an amended licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, noninvasive drug delivery platform (the Eyelid Drug Delivery Platform
- CHMP Recommends EU Approval of Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/chmp-recommends-eu-approval-of-enspryng-satralizumab-for-neuromyelitis-optica-spectrum-disorder-nmosd/2479111/Chugai Pharmaceutical announced that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody